Publications by authors named "Sarah Holstein"

Claim this Profile
T
The effects of geranylgeranyl diphosphate synthase inhibitor treatment on osteoblast biology and application in a conditioned media model of myeloma bone disease.
Molly E Muehlebach, Sarah A Holstein

Bone Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mouse Models of Osteosarcoma: Unraveling Disease Mechanisms and Accelerating Drug Discovery and Development.
Staci L Haney, Sarah A Holstein

Cancer Rep (Hoboken)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Home Is Where the Research Is: The Promise of Decentralized Clinical Trials.
Sarah A Holstein

Clin Pharmacol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.
Sarah A Holstein, Shebli Atrash, Hira Mian, Meletios A Dimopoulos, Fredrik Schjesvold

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the unfolded protein response pathway in bone homeostasis and potential therapeutic target in cancer-associated bone disease.
Molly E Muehlebach, Sarah A Holstein

Bone Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML.
Vijaya R Bhatt, Christopher S Wichman, Thuy T Koll, Alfred L Fisher, Tanya M Wildes, Sarah A Holstein

Am J Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Reflection on the Evolution of Antibody-Based Therapies in Oncology: Trastuzumab as an Exemplar-Commentary on Dijkers et al.
Sarah A Holstein

Clin Pharmacol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of fixed phosphorus position on activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Md Ayub Ali, Mona A Maalouf, Dan Feng, Mamunur Rashid, Nathaniel R Gehrke, Sarah A Holstein

Bioorg Med Chem· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship of isoprenoid triazole bisphosphonate-based geranylgeranyl diphosphate synthase inhibitors: Effects on pharmacokinetics, biodistribution, and hepatic transporters.
Staci L Haney, Yashpal S Chhonker, Mamunur Rashid, Daryl J Murry, Sarah A Holstein

Drug Metab Dispos· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.
Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don Benson

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data.
Moataz Ellithi, Magdi Elsallab, Matthew A Lunning, Sarah A Holstein, Smriti Sharma

Transplant Cell Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging Real-World Data to Address Potential Methadone Drug-Drug Interactions.
Sarah A Holstein

Clin Pharmacol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Sarah A Holstein

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity.
Molly E Muehlebach, Staci L Haney, Yashpal S Chhonker, Mamunur Rashid, Daryl J Murry, Sarah A Holstein

JBMR Plus· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in targeted drug delivery systems for multiple myeloma.
Ashruti Pant, Aayushi Laliwala, Sarah A Holstein, Aaron M Mohs

J Control Release· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of an LC-MS/MS Assay for the Quantitation of MO-OH-Nap Tropolone in Mouse Plasma: Application to In Vitro and In Vivo Pharmacokinetic Studies.
Wafaa N Aldhafiri, Yashpal S Chhonker, Nusrat Ahmed, Sandeep K Singh, Staci L Haney, Sarah A Holstein

Molecules· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Sarah A Holstein

Am J Hematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Sarah A Holstein

Blood Cancer J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Sarah A Holstein

Br J Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
α-Amino bisphosphonate triazoles serve as GGDPS inhibitors.
Nathaniel R Gehrke, Dan Feng, Md Ayub Ali, Mona A Maalouf, Sarah A Holstein

Bioorg Med Chem Lett· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach, Sarah A Holstein

Blood Cancer J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the activity of a novel tropolone in osteosarcoma.
Staci L Haney, Dan Feng, Sai Sundeep Kollala, Yashpal S Chhonker, Michelle L Varney, Sarah A Holstein

Drug Dev Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy.
Andrew C Pham, Sarah A Holstein, Gloria E O Borgstahl

Mol Cancer Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia.
Vijaya R Bhatt, Christopher Wichman, Thuy T Koll, Alfred L Fisher, Tanya M Wildes, Sarah A Holstein

J Geriatr Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Sarah A Holstein

Lancet Haematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis